ReviewCancer research2021
Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers.
Open access · bronzeAbstract readHistorical ArticleReview
In one paragraph
Review in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 62 citations in OpenAlex.
- Paediatric therapeutic development workshop on medulloblastoma.British journal of cancer · 2026Review
- Protein Modifications for Cellular Protein Delivery.Chemical reviews · 2026Review
- A Conserved Enhancer Locus in Extrachromosomal DNA and Homogeneously Staining Regions Activates MYC Transcription in Group 3 Medulloblastoma.Cancer research · 2026Article
- Amplification of MED30 at chromosome 8q24 reprograms MYC binding to low-affinity oncogenic enhancers in cancer cells.Cell reports · 2026Article
- Targeting the MYCN interaction network in neuroblastoma.Bioscience reports · 2026Review
- MYCN Amplification Drives Ferroptosis Susceptibility via Cysteine Metabolism in Retinoblastoma.Investigative ophthalmology & visual science · 2026Article
- ZRANB1 depletion inhibits neuroblastoma progression by destabilizing MYCN through EZH2-mediated deubiquitination.Cell biology and toxicology · 2026Article
- The N-Myc MB0-MBI region interacts specifically and dynamically with the N-lobe of Aurora kinase A.Nature communications · 2026Article
- Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma.Journal of medicinal chemistry · 2025Article
- Extracellular Vesicle microRNAs in the Crosstalk Between Cancer Cells and Natural Killer (NK) Cells.Cells · 2025Review
- Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis.NPJ precision oncology · 2025Article
- Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?Genes & diseases · 2025Review
- Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders.Cell chemical biology · 2025Article
- TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.Scientific reports · 2025Article
- Article
- PLK4 as a Key Regulator of Neuroblastoma Differentiation and a Promising Therapeutic Target.International journal of biological sciences · 2025Article
- Molecular regulation and therapeutic targeting ofFrontiers in cell and developmental biology · 2025Review
- MYCN as an oncogene in pediatric brain tumors.Frontiers in oncology · 2025Review
- A Small Molecule Selectively Targets N-Myc to Suppress Neuroblastoma Cancer Progression.International journal of biological sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 19 institutions in 4 countries.
Adam J WolpawDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.ORCID 0000-0002-1373-7648
Richard BaylissAstbury Center for Structural Molecular Biology, School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom.ORCID 0000-0003-0604-2773
Gabriele BüchelDepartment of Biochemistry and Molecular Biology, Theodor Boveri Institute, Biocenter, University of Wuürzburg, Wuürzburg, Germany.ORCID 0000-0001-7070-7341
Chi V DangWistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-4031-2522
Martin EilersDepartment of Biochemistry and Molecular Biology, Theodor Boveri Institute, Biocenter, University of Wuürzburg, Wuürzburg, Germany.
W Clay GustafsonUniversity of California San Francisco, UCSF Benioff Children's Hospital, San Francisco, California.
Gwenn H HansenNurix Therapeutics, San Francisco, California.ORCID 0000-0003-2504-5849
Natalia JuraCardiovascular Research Institute, University of California San Francisco, San Francisco, California.
Stefan KnappInstitut für Pharmazeutische Chemie und Structural Genomics Consortium, Goethe-University Frankfurt, Frankfurt, Germany.ORCID 0000-0001-5995-6494
Mark A LemmonDepartment of Pharmacology and Cancer Biology Institute, Yale School of Medicine, New Haven, Connecticut.
David LevensLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. mosse@chop.edu maris@chop.edu.ORCID 0000-0002-8088-7929
Ronen MarmorsteinPerelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0003-4373-4752
Steven J MetalloDepartment of Chemistry, Georgetown University, Washington, DC.
Julie R ParkDepartment of Pediatrics, University of Washington School of Medicine and Center for Clinical and Translational Research, Seattle Children's Hospital, Seattle, Washington.
Linda Z PennPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.ORCID 0000-0001-8133-5459
Michael RapeHoward Hughes Medical Institute, University of California at Berkeley, Berkeley, California.
Martine F RousselDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Kevan M ShokatHoward Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California.ORCID 0000-0001-8590-7741
William P TanseyVanderbilt University School of Medicine, Nashville, Tennessee.
Kliment A VerbaDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California.ORCID 0000-0002-2238-8590
Seychelle M VosDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
William A WeissDepartments of Neurology and Pediatrics, Neurological Surgery and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.ORCID 0000-0003-2230-9132
Elmar WolfCancer Systems Biology Group, Theodor Boveri Institute, University of Würzburg, Würzburg, Germany.ORCID 0000-0002-5299-6335
Yaël P MosséDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. mosse@chop.edu maris@chop.edu.ORCID 0000-0002-3463-0399
University of Würzburg · DEChildren's Hospital of Philadelphia · USHoward Hughes Medical Institute · USThe Wistar Institute · USUniversity of California, San Francisco · USGeorgetown University · USGoethe University Frankfurt · DEMassachusetts Institute of Technology · USNational Cancer Institute · USNurix (United States) · USPrincess Margaret Cancer Centre · CASeattle Children's Hospital · USSt. Jude Children's Research Hospital · USUCSF Benioff Children's Hospital · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Leeds · GBUniversity of Pennsylvania · USVanderbilt University · USYale Cancer Center · US
Funding
Tumor microenvironment-dependent therapy resistanceP01CA217959 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$20.7Mc-Myc FunctionZIABC011465 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LEVENS, DAVID L. · 2012 to 2025
$8.6MMolecular Mechanisms, Pathways and Inhibition of Acetyl-Transfer ReactionsR35GM118090 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Ronen Marmorstein · 2016 to 2026
$6.7MResearch Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0MInhibitors of the G protein GNAS which drives pancreatic tumorigenesisR01CA244550 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHOKAT, KEVAN M. · 2020 to 2024
$2.0MCancer Research UK 23302NCI NIH HHS P01 CA217959NCI NIH HHS R01 CA244550NCI NIH HHS T32 CA128583NIGMS NIH HHS R35 GM118090
Abstract
Effective treatment of pediatric solid tumors has been hampered by the predominance of currently "undruggable" driver transcription factors. Improving outcomes while decreasing the toxicity of treatment necessitates the development of novel agents that can directly inhibit or degrade these elusive targets. MYCN in pediatric neural-derived tumors, including neuroblastoma and medulloblastoma, is a paradigmatic example of this problem. Attempts to directly and specifically target MYCN have failed due to its similarity to MYC, the unstructured nature of MYC family proteins in their monomeric form, the lack of an understanding of MYCN-interacting proteins and ability to test their relevance
Indexed as
Drug Resistance, NeoplasmTherapies, InvestigationalAge of OnsetAntineoplastic AgentsChildDrug DiscoveryDrug Screening Assays, AntitumorGene Expression Regulation, NeoplasticHistory, 20th CenturyHistory, 21st CenturyHumansNeoplasmsN-Myc Proto-Oncogene ProteinAntineoplastic AgentsMYCN protein, humanN-Myc Proto-Oncogene Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.